Skip to main content

Secondary Navigation

  • Our Products
    • Product Replacement
  • Investors
    • Financials
    • Investor Resources
  • News
  • Contact Us
Home

Primary navigation

  • Our Company
    • What We Do
    • A Story of Transformation
    • Partnerships
  • Our Science
    • Therapeutic Focus Areas
    • Technologies and Platforms
    • Pipeline
    • Medical Publications
    • Medical Affairs
  • Patients
    • Our Commitment
    • Patient Advocacy
    • Clinical Studies
    • Resources
  • Our People
    • Executive Leadership
    • Careers

News and Events

news-bi
news-si
  • All
  • Events
  • Press Releases
press release
October 12, 2020

Immunomedics Announces FDA Orphan Drug Designation of Trodelvyᵀᴹ for Glioblastoma

event-19092020
September 19, 2020

Immunomedics ESMO 2020 Update Call

press release
September 19, 2020

Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvyᵀᴹ in Metastatic Urothelial Cancer

press release
September 19, 2020

Trodelvyᵀᴹ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer

press release
September 18, 2020

Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers

press releases
September 9, 2020

Immunomedics Announces Key Oral Presentations at ESMO 2020

press releases
September 2, 2020

Immunomedics to Participate in Upcoming Healthcare Conferences

press releases
August 17, 2020

Immunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer of Trodelvyᵀᴹ

Press releases
August 5, 2020

Immunomedics Announces Second Quarter 2020 Results and Provides Corporate Update

press releases
July 27, 2020

Immunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5, 2020

Pagination

  • First page <<
  • Previous page <
  • Page
  • 1
  • / 4
  • Next page >
  • Last page >>

Footer

  • Our Company
  • Patients
  • Our People
  • Our Products
  • News
  • Careers
  • Our Science
  • Investors
  • Contact Us
  • Partnerships
©Immunomedics

Legal Menu

  • Internet Policy
  • Legal Statement